This is a paid advertisement.
| This could be the most important medical discovery in decades. It could be worth billions worldwide! And I expect this to propel ARTH
shares 300 to 500 this year alone!   | |  Fellow Investor: For decades, bleeding complications have been a major problem in surgery, often triggering life-threatening nightmares for surgeons, doctors and patients. That's not all. Bleeding control is essential trauma response, especially in the military where it is the number one cause of death on the battlefield. Even at home, bleeding control from scrapes and cuts depends on a 100-year old approach that may soon be obsolete. This breakthrough product from Arch Therapeutics (ARTH) could be worth a fortune to you, if you act immediately. Here's why. Arch Therapeutics is preparing its breakthrough bleeding control product, AC5™, for final phases to market... and I'm strongly recommending ARTH as an immediate buy.
This may be your last chance to catch ARTH early. The profit potential in ARTH today is simply enormous. If you're excited about catching a breakout early, you'll want to read my new online report right now. It reveals details how:  | Arch Therapeutics gained exclusive licenses to the product from the Massachusetts Institute of Technology...... | | | Pre-clinical trials confirmed its efficacy with stunning results... | | | It is now entering human trials to regulatory approval, which is the pivotal point for ground floor investing... | | | A stellar team of world-renown medical researchers, surgeons and medical products specialists are preparing to bring this product to market... | | | Surgeons are already calling this the "Holy Grail" that could be used in "80% of cases"... | | | Its European introduction should accelerate regulatory approvals to explosive growth in America... | And most important for investors... This is the entry point where ARTH remains off-radar, unknown to even seasoned biotech investors! But with final phases of product trials and approvals underway, this won't last long! A buy now in ARTH can put you weeks ahead of a rush that could rapidly triple, even quintuple ARTH into the $3.00 to $5.00 range this year. Yes, that means you can still own ARTH shares for around a dollar! Don't expect that to last. Arch Therapeutics clearly qualifies as one of the best medical technology stocks I've uncovered in my career. The product is a genuine breakthrough, its uses are global, and the profit potential for shareholders is stunning. You can get all the details on this emerging story through my new report. I urge you to read it now! Yours for Profit,  Ian Cooper, Publisher
Speed Retirement System Newsletter 
  View Important Disclaimer Here | |
=================================
=================================
This is a communication from The Stock Junction.
This is a paid advertisement provided to our customers. Although we have sent you this email, The Stock Junction does not endorse this product or company nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above, and have not independently reviewed the information provided within this advertisement.
Champlain Media, publisher of The Stock Junction, has been paid a total of three thousand dollars by a third party on behalf of Arch Therapeutics, Inc. (OTCBB:ARTH) for the distribution of this and other email advertisements. The opinions represented in this email advertisement are not those of Champlain Media.
We respect your privacy and therefore this email has been sent directly from The Stock Junction. The Stock Junction does not provide our email lists and other data to third parties. This is consistent with our Privacy Policy as outlined on our web site. You may review it at:
http://www.thestockjunction.com/privacy
If you do not want to receive future communications from Champlain Media, please follow the unsubscribe instructions below.
========================
Unsubscribe Instructions
========================
You are subscribed with the following email address: ignoble.experiment@arconati.us
To unsubscribe from Champlain Media emails click here: http://www.thestockjunction.com/unsub/
If you believe this communication to be a mistake or unsolicited, please e-mail abuse@champlainmedia.com with details regarding your situation, and we will be sure to promptly investigate your situation.
A publication of Champlain Media
65 Railroad Street
Richmond, VT 05477
PO Box 790
No comments:
Post a Comment
Keep a civil tongue.